Altered pulmonary blood volume distribution as a biomarker for predicting outcomes in COVID-19 disease.
Journal
The European respiratory journal
ISSN: 1399-3003
Titre abrégé: Eur Respir J
Pays: England
ID NLM: 8803460
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
09
11
2020
accepted:
03
02
2021
pubmed:
27
2
2021
medline:
23
9
2021
entrez:
26
2
2021
Statut:
epublish
Résumé
Evidence suggests that vascular inflammation and thrombosis may be important drivers of poor clinical outcomes in patients with COVID-19. We hypothesised that a significant decrease in the percentage of blood volume in vessels with a cross-sectional area between 1.25 and 5 mm We performed a retrospective analysis of chest CT scans from 10 hospitals across two US states in 313 COVID-19-positive and 195 COVID-19-negative patients seeking acute medical care. BV5% was predictive of outcomes in COVID-19 patients in a multivariate model, with a BV5% threshold below 25% associated with OR 5.58 for mortality, OR 3.20 for intubation and OR 2.54 for the composite of mortality or intubation. A model using age and BV5% had an area under the receiver operating characteristic curve of 0.85 to predict the composite of mortality or intubation in COVID-19 patients. BV5% was not predictive of clinical outcomes in patients without COVID-19. The data suggest BV5% as a novel biomarker for predicting adverse outcomes in patients with COVID-19 seeking acute medical care.
Identifiants
pubmed: 33632795
pii: 13993003.04133-2020
doi: 10.1183/13993003.04133-2020
pmc: PMC7908189
pii:
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright ©The authors 2021.
Déclaration de conflit d'intérêts
Conflict of interest: M.F. Morris has nothing to disclose. Conflict of interest: Y. Pershad has nothing to disclose. Conflict of interest: P. Kang has nothing to disclose. Conflict of interest: L. Ridenour has nothing to disclose. Conflict of interest: B. Lavon is an employee of FLUIDDA, a company that develops and markets part of the technology described in this paper. Conflict of interest: M. Lanclus is an employee of FLUIDDA, a company that develops and markets part of the technology described in this paper. Conflict of interest: R. Godon is an employee of FLUIDDA, a company that develops and markets part of the technology described in this paper. Conflict of interest: J. De Backer is an employee of FLUIDDA, a company that develops and markets part of the technology described in this paper. Conflict of interest: M.K. Glassberg serves on advisory boards for Bellerophon Therapeutics, Genentech, Boehringer Ingelheim and Bristol Myers Squibb.